What Fueled The Previous Growth In The Aspergillosis Treatment Market?
The aspergillosis treatment market has seen considerable growth due to a variety of factors.
• The market size for aspergillosis treatment has seen robust growth in the past years. Projected to surge from $3.14 billion in 2024 to $3.33 billion in 2025, it exhibits a compound annual growth rate (CAGR) of 5.8%.
This significant growth in the previous period is a result of advances in diagnostics, a higher demand for antifungal drugs, an increased rate of incidence, and invasive procedures.
How Does the Forecast Look for the Aspergillosis Treatment Market?
The aspergillosis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for aspergillosis treatment is projected to experience robust growth in the upcoming years, reaching a value of $4.28 billion by 2029, with a compound annual growth rate (CAGR) of 6.5%.
The rise during this forecast period can be linked to the demand for transplantation medicine, the incidence of hematologic malignancies, the escalation in research and development investments, and public health efforts. Notable trends in this period include resistance to antifungal therapies, the advent of targeted treatments, therapeutic drug tracking, as well as drug development.
What Are The Leading Drivers Of Growth In The Aspergillosis Treatment Market?
The escalating occurrence of fungal infections is projected to fuel the advancement of the aspergillosis treatment market in the future. Mycosis, or fungal infections, are diseases that fungi origin and can lead to infections in both humans and animals. Aspergillosis, a type of fungal infection, has the potential to infect various body parts including the respiratory system, lungs, brain, kidneys, and other organs. Treatments for aspergillosis like voriconazole aim to regulate the fungal infection, alleviate its symptoms, avoid complications, and boost overall health. For example, The Health Security Agency, a government agency from UK, reported in September 2023 that bloodstream infections due to yeast per 100,000 population in England escalated from 3.8 in 2021 to 4.0 in 2022. Thus, the escalation in mycosis occurrences is steering the growth of the aspergillosis treatment market.
Aspergillosis Treatment Market Driver: Soaring Healthcare Expenditures Catalyzing The Aspergillosis Treatment Market
How Are The Segments Defined Within The Global Aspergillosis Treatment Market?
The aspergillosis treatment market covered in this report is segmented –
1) By Type: Allergic Aspergillosis, Chronic Aspergillosis, Invasive Aspergillosis, Other Type
2) By Drug Class: Corticosteroids, Antifungal drugs, Other Drug Class
3) By Route of Administration: Oral, Injectable, Other Route Of Administration
4) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Other Distribution Channel
Subsegments:
1) By Allergic Aspergillosis: Allergic Fungal Sinusitis, Allergic Bronchopulmonary Aspergillosis (ABPA)
2) By Chronic Aspergillosis: Chronic Pulmonary Aspergillosis, Chronic Cavitary Aspergillosis
3) By Invasive Aspergillosis: Pulmonary Invasive Aspergillosis, Disseminated Invasive Aspergillosis
4) By Other Type: Aspergilloma, Other Rare Forms of Aspergillosis
Pre-Book The Aspergillosis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Aspergillosis Treatment Industry?
Major firms in the aspergillosis treatment market are committed to developing and launching novel aspergillosis medications to maintain their market standing. The creation of new drugs broadens the range of treatments for aspergillosis, like posaconazole oral suspension that offers more targeted and effective treatment for patients. For example, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, introduced Posaconazole oral suspension in the US in April 2023 as a treatment for aspergillosis. These drugs are particularly suitable for patients at a high risk of developing invasive aspergillus and candida infections, such as those with severely weakened immune systems like hematopoietic stem cell transplant (HSCT) recipients suffering from graft-versus-host disease (GVHD). Also, Posaconazole oral suspension is advised for the treatment of Oropharyngeal candidiasis (OPC), specifically when it is resistant to itraconazole and fluconazole.
Who Are the Key Players In The Aspergillosis Treatment Market?
Major companies operating in the aspergillosis treatment market are:
• Basilea Pharmaceutica Ltd.
• Pfizer Inc.
• Johnson and Johnson
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Merck and Co. Inc.
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries
• Astellas Pharma Inc.
• Regeneron Pharmaceuticals
• Mylan N.V.
• Sun Pharmaceutical Industries
• Jazz Pharmaceuticals
• Dr. Reddy's Laboratories
• Cipla Ltd.
• Bruker Corporation
• Hikma Pharmaceuticals PLC.
What Is The Most Dominant Region In The Aspergillosis Treatment Market?
North America was the largest region in the aspergillosis treatment market in 2024. The regions covered in aspergillosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
